Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Arcellx, Inc.
University of Kansas Medical Center
Zhujiang Hospital
Ryvu Therapeutics SA
Guangzhou Lupeng Pharmaceutical Company LTD.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Melbourne Health
Biocity Biopharmaceutics Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jasper Therapeutics, Inc.
M.D. Anderson Cancer Center
University College, London
Institut Paoli-Calmettes
King's College London
Benovus Bio, Inc.
Seoul St. Mary's Hospital
National Cancer Institute (NCI)
Peter MacCallum Cancer Centre, Australia